<SEC-DOCUMENT>0001558370-25-000123.txt : 20250110
<SEC-HEADER>0001558370-25-000123.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110161524
ACCESSION NUMBER:		0001558370-25-000123
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250110
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO-PATH HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001133818
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				870652870
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36333
		FILM NUMBER:		25523154

	BUSINESS ADDRESS:	
		STREET 1:		4710 BELLAIRE BOULEVARD
		STREET 2:		SUITE 210
		CITY:			BELLAIRE
		STATE:			TX
		ZIP:			77401
		BUSINESS PHONE:		(832) 742-1357

	MAIL ADDRESS:	
		STREET 1:		4710 BELLAIRE BOULEVARD
		STREET 2:		SUITE 210
		CITY:			BELLAIRE
		STATE:			TX
		ZIP:			77401

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO-PATH HOLDINGS INC
		DATE OF NAME CHANGE:	20080221

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OGDEN GOLF CO CORP
		DATE OF NAME CHANGE:	20010205
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bpth-20250110x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 1/10/2025 7:43:54 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: f6d26244-456b-44bc-a5e0-6f928cec3abd -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:bpth="http://www.biopathholdings.com/20250110" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:EntityCentralIndexKey" id="Tc_yjcFpQsgIEOKWpV7R2277A_2_1">0001133818</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:AmendmentFlag" id="Tc_jZhUsFsLLkuqzil6UW9vfw_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="bpth-20250110.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001133818</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-10</xbrli:startDate><xbrli:endDate>2025-01-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_313e22a9_a1e5_40b2_ad9c_fc71df165147"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:DocumentType" id="Narr_NGTMmHhZPkO7Gi-KAYdkCg"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT PURSUANT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TO SECTION 13 OR 15(d) OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_sPUBaSvaqUWrWosRHHTocg">January 10, 2025</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:EntityRegistrantName" id="Narr_hueI6ui5MkuypjsGQX1-bQ"><b style="font-weight:bold;">BIO-PATH HOLDINGS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_099f6d2f_030a_4459_b727_9bb84fa19564"></a><a id="Tc_tke2EDOf9EK4iNrikczEFg_2_0"></a><a id="Tc_FV3gt6F9-EuRhvCJNnMiUQ_2_2"></a><a id="Tc_oWb512ptoUyUyFxdN31vtQ_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:29.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32.45%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_9T_M8owlL0Se5AIhwVuygg_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:32.46%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:EntityFileNumber" id="Tc_TaRGEEgpb06lJnlZ75mDGw_1_2"><b style="font-weight:bold;">001-36333</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:29.51%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:EntityTaxIdentificationNumber" id="Tc_T6WWZ-JONE6YvjCGGfuWlA_1_4"><b style="font-weight:bold;">87-0652870</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction of&#160;incorporation)</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission File Number)</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_82bd9145_e45d_4524_bf8a_11c4ecded9bf"></a><a id="Tc_1DJ44ONYj0CKbvCmd41HyA_1_0"></a><a id="Tc_WV4E-w55UEOANVTIcXLrYQ_2_0"></a><a id="Tc_axc3KEO6hUGj6mjLf8hGkg_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:61.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:36.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:61.19%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:EntityAddressAddressLine1" id="Narr_Mj7AJt2nVE20bu4-keeE_A"><b style="font-weight:bold;">4710 Bellaire Boulevard</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:EntityAddressAddressLine2" id="Narr_wEsVccafY0qCzI5__9GxCw"><b style="font-weight:bold;">Suite 210</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:EntityAddressCityOrTown" id="Narr_5-dZTqpOSUqcJa1IDb1Www"><b style="font-weight:bold;">Bellaire</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_Ibut8vBwik2TyyvL6sPC_w"><b style="font-weight:bold;">Texas</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:36.01%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:EntityAddressPostalZipCode" id="Tc_8NXNcfObNU--p3hUYO6WNQ_1_2"><b style="font-weight:bold;">77401</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:61.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:CityAreaCode" id="Narr_dLkV_PBbnESFexeIv0BD-g">832</ix:nonNumeric>) <ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:LocalPhoneNumber" id="Narr_BHs3bGy_Jki8JdNbpkXs_A">742-1357</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c1c81fef_4b89_4666_9f87_15e11e042cf6"></a><a id="Tc_uOs13mZfkk6aqwOHWQm5Zw_1_1"></a><a id="Tc_j7NiggRWwEOGtxu6vms8-w_2_1"></a><a id="Tc_KD-AokscLU2lt7RCa0Ns2g_3_1"></a><a id="Tc_CB0vfp66E02ZPV7Y2S3zkA_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_nk09Mq3aNU-DYisFGLsaeA_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_sSvqhKuAz0qkIoz-3-hsAw_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_Y3BkdsRC_0SgximsULO2PQ_3_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_B041nSXjJUucWJnXknuGbg_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ef01f4d9_e9c2_434b_93b5_c0080e1dbf88"></a><a id="Tc_v3Gz8H5hskOySG-z7Xz6Dw_1_0"></a><a id="Tc_nCiz9CGS-kCZuVhNQH4jLw_1_2"></a><a id="Tc_u3D3-iH9YUGFs-lV65Xe-Q_1_4"></a><a id="Tc_HrUWOOC1zEyfbqOfwbtUjQ_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:37.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.96%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:19.95%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol</p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:37.95%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:37.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:Security12bTitle" id="Tc_4rQ8W00AEkSdLf-Af2PkSg_2_0">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:19.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" name="dei:TradingSymbol" id="Tc_eO1IJwELkUSQmtoc6-GcXQ_2_2">BPTH</ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:37.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The <ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_beFinRF-q0ChyoM3PUSgdg">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_Ut5KOlhftEyG84YDIkESqg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_423ad77f_68a9_42e7_9a70_68301d9067a0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 7.01 Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On January 10, 2025, Bio-Path Holdings, Inc. (the &#8220;Company&#8221;) issued a press release titled, &#8220;Bio-Path Holdings Provides 2025 Clinical and Operational Update.&#8221; A copy of such press release is attached hereto as Exhibit 99.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_2d5787c6_2b24_4e82_8105_38eb438b55ba"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(d) <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:89.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Number</span></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:89.99%;margin:0pt;padding:0pt 0pt 1.25pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description</span></p></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bpth-20250110xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">99.1</span></a></p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="bpth-20250110xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press release dated January 10, 2025.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:89.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d0325edb_811e_4cba_9aea_5693f9f44bfc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BIO-PATH HOLDINGS, INC.</b> &#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: January 10, 2025</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:top;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter H. Nielsen</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter H. Nielsen</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>bpth-20250110xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 1/10/2025 07:43:50 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"><img src="bpth-20250110xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:39.45pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:185.3pt;"></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;">Bio-Path Holdings Provides 2025 Clinical and Operational Update</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;">Advancing Multiple Programs in Areas of Significant Unmet Medical Need</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;">Several Milestones Across Clinical Development Pipeline Expected in 2025</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;">HOUSTON&#8212;January 10, 2025 </b><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">&#8211; </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize&#174; liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today provides a clinical development and operational update for 2025. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;line-height:8pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">&#8220;The important work we conducted throughout 2024 has led us into what we believe is an exciting 2025 as we build off positive data generated in oncology and the addition of a new application for BP1001-A in the treatment of obesity for Type 2 Diabetes. This new application compels us to advance these studies as quickly as possible and to file for regulatory designations that could accelerate our path to approval,&#8221; said Peter H. Nielsen, President and Chief Executive Officer of Bio-Path. &#8220;There is no greater challenge than the battle against cancer, and developing effective new medicines for patients suffering with few treatment options is what drives us every day. The addition of development of a potential treatment for obesity in Type 2 Diabetes patients follows this pathway as these patients need treatment beyond current weight loss drugs to support needed therapy for reducing glucose levels, which has positive impact across a number of different health-related conditions. The substantial progress we have made gives us further confidence that our DNAbilize&#174; platform is ushering in a new path of DNA-powered medicines that can make a difference in the lives of these patients.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Program Overview</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Bio-Path&#8217;s clinical development program consists of one Phase 2 clinical trial, two Phase 1 or 1/1b clinical trials, and two preclinical programs. Bio-Path has developed a molecular biomarker package for its Phase 2 clinical trial in acute myeloid leukemia (AML) that was developed to identify patients that potentially have a higher propensity to respond to prexigebersen treatment. &#160;Bio-Path expects to utilize the biomarker package to accompany prexigebersen treatment in 2025 and expects to evaluate prexigebersen for the treatment of obesity. In addition, BP1001-A is in preclinical development for treatment of obesity in Type 2 Diabetes patients, which may be submitted to the U.S. Food and Drug Administration (FDA) later in the year in an Investigational New Drug (IND) application. &#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;">Development of Molecular Biomarkers</i><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> &#8211; Bio-Path has developed a molecular biomarker package to accompany prexigebersen treatment, the goal of which is to identify patients with a genetic profile more likely to respond to treatment thereby improving probability of success for this program. The emerging role of biomarkers has been enhancing cancer development over the past decade and has become a more common companion to many cancer development programs. Bio-Path expects to utilize the prexigebersen biomarkers in 2025 in the Phase 2 AML clinical trial and to develop additional molecular biomarker packages to accompany its new programs.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;">Prexigebersen Phase 2 Clinical Trial</i><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> &#8211; Bio-Path&#8217;s Phase 2 clinical trial for the treatment of AML is comprised of three cohorts of patients and treatments, each separately approvable by the FDA as a new indication. The first two cohorts are treating patients with the triple combination of prexigebersen, decitabine and venetoclax. The first cohort includes untreated AML patients, and the second cohort includes relapsed/refractory AML patients. Finally, the third cohort is treating relapsed/refractory AML patients who are venetoclax-resistant or intolerant with the two-drug combination of prexigebersen and decitabine. Outcomes for these older patients who are unable to receive intensive chemotherapy due to the challenging side effect profile, remain suboptimal with a median survival of only 5 to 10 months.  Bio-Path also expects to utilize an advisory panel of AML experts to assist in the design of the final clinical development plans through potential FDA approval.  Other significant milestones expected during 2025 include the completion of Cohort 2 and an interim analysis for Cohort 3.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;">Phase 1/1b Clinical Trial in BP1001-A in Advanced Solid Tumors</i><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;"> &#8211; A Phase 1/1b clinical trial of BP1001-A in patients with advanced or recurrent solid tumors, including ovarian and uterine, pancreatic and breast cancer, is ongoing. BP1001-A is a modified product candidate that incorporates the same drug substance as prexigebersen but has a slightly modified formulation designed to enhance nanoparticle properties. The Phase 1 study has advanced to the second, higher dose level and the first patient in the second dose cohort continued experiencing a positive response which may signal that this analog of prexigebersen has potential as a new treatment for advanced solid tumors. The patient continues to be doing well after ten months on study after failing extensive chemotherapy and surgical treatment for gynecologic cancer, demonstrating a 15% reduction in her primary tumor through nine cycles of treatment.  Moreover, it appears that these positive outcomes may have contributed to allowing her to continue with rigorous exercise and improved quality of life.  Completion of the second and third dosing cohorts are expected in 2025.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">The Phase 1b portion of the study is expected to commence after successful completion of the three BP1001-A monotherapy dose level cohorts and is intended to assess the safety and efficacy of BP1001-A in combination with paclitaxel in patients with recurrent ovarian or endometrial tumors. Phase 1b studies are also expected to be initiated in combination with gemcitabine in Stage 4 pancreatic cancer and combination therapy in breast cancer.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;">Phase 1/1b Clinical Trial in BP1002 in Relapsed/Refractory AML</i><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> &#8211; A Phase 1/1b clinical trial for BP1002 to treat relapsed/refractory AML patients, including venetoclax-resistant patients, is ongoing. BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Venetoclax treats AML patients by blocking the activity of the Bcl-2 protein in AML patients. However, over time patients become resistant to venetoclax. BP1002 treats the Bcl-2 target by blocking the cell&#8217;s ability to produce Bcl-2 and could provide benefit for these venetoclax resistant patients. AML patients that fail frontline venetoclax-based therapy have very poor prognosis with median overall survival of less than three months. The first dose cohort consisted of a starting dose of 20 mg/m2, the second dose cohort of 40 mg/m2 and there were no dose limiting toxicities. The third dosing cohort of 60 mg/m2 is open and enrollment closed faster than expected which Bio-Path believes reflects the need for additional treatment options.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:italic;">Prexigebersen as Potential Treatment for Obesity in Type 2 Diabetes Patients</i><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"> &#8211; BP1001-A downregulates Grb2 expression to increase insulin sensitivity and helps lower blood glucose level in Type 2 diabetes patients. Scientific evidence suggests that by downregulating Grb2 expression, BP1001-A could help lower blood glucose levels by affecting insulin signaling. Bio-Path conducted preclinical studies that confirmed the effectiveness of BP1001-A in affecting insulin signaling and its potential efficacy as a therapeutic treatment for obese patients who have Type 2 diabetes. In 2025, Bio-Path expects to complete preclinical testing and to file an IND.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property Protection </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;white-space:pre-wrap;">Bio-Path&#8217;s composition of matter patents are designed to protect encroachment from third parties on its proprietary products. These composition patents allow the Company to apply its core technology to new protein targets and receive new 20-year patents.  Bio-Path&#8217;s patent portfolio is as follows:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:9.5pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Composition and methods of use patents issued cover DNAbilize technology, solely owned by Bio-Path.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-style:normal;font-weight:normal;">Seven patents issued in the U.S. with one additional application allowed; 61 foreign patents issued across 24 countries; five additional foreign patent applications allowed; three applications pending in the U.S. along with more than 30 applications pending in foreign jurisdictions.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">About Bio-Path Holdings, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Bio-Path is a biotechnology company developing DNAbilize&#174;, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path&#8217;s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company&#8217;s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">For more information, please visit the Company&#39;s website at </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">www.biopathholdings.com</font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">. &#160; </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forward-Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;line-height:8pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"> </font><font style="font-family:'Times New Roman','Times','serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These statements are based on management&#39;s current expectations and accordingly are subject to uncertainty and changes in circumstances. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path&#8217;s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies, the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, the maintenance of intellectual property rights, that patents relating to existing or future patent applications will be issued or that any issued patents will provide meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith, and such other risks which are identified in Bio-Path&#39;s most recent Annual Report on Form&#160;10</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">-</font><font style="font-family:'Times New Roman','Times','serif';">&#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">K, in any subsequent quarterly reports on Form 10-Q and in other reports that Bio-Path files with the Securities and Exchange Commission from time to time. These documents are available on request from Bio-Path or at </font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">www.sec.gov</font><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;"># # #</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Contact Information:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;font-weight:bold;">Investors</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Will O&#8217;Connor</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Stern Investor Relations, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">212-362-1200</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">will@sternir.com</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Doug Morris </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Investor Relations </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">Bio-Path Holdings, Inc. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:9.5pt;">832-742-1369</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>bpth-20250110xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 bpth-20250110xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !/ 7,# 2(  A$! Q$!_\0
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ME/\ @D;^S3X,UCX;:A\1M?T.SUK7)[U[6T>_A69+:-.I16! 8GO0!]%_ ?\
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M73-?_:'^*DWC2STYP\.CV3.5?!SM+$ *#WVKD^M '+_LQ?\ !.#P7\??V;?
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MY-[I\+1F%7Y'#=2" : /-?V;Y W_  2QOL'.-%O1D?4UT/\ P2+_ .34+?\
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M#;&Z''UR*]8_:^\;6'@SX!>*I;R=(Y;VU-G;QL>9)'XP!],FO,?BC^Q/J?\
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MNJ0:M++=O<B:"-D #8XP:K&8RC5I5HPEK)QM\EJ+"86K3J4Y26B4K_-GD/\
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M *+MXG_\ K;_  H]E3_Y^+[F+VU3_GV_P/?MX]#1O'O7@(_9Y^(?_1=O$_\
MX!6W^%!_9Z^(F/\ DNWB8?\ ;E;?X4_94O\ GXON?^0>VJ?\^W^![]O%9GBC
MQ!!X5\.ZGK%RCR6]A;274B1_>*HI8@>_%<#\-/A7XJ\%Z[)>:W\2]8\86K1%
M%LK^VBC16_O H,YKH/C./^+3>,?^P3=?^BFKGG%1=HNYTPDY*[5CR_1_VUO
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M/^?;^]'OOXT<'J:\"_X9Y^(O_1=_$W_@';_X4O\ PSU\1?\ HN_B;_P#M_\
M"CV5+_GXON?^0>UJ?\^W]Z/?"012#!]J\$_X9Z^(O_1=_$W_ (!V_P#A2?\
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M,MAJ#P)*0,!BHXSCN*:FUH%D>\?#CQI9_$7P+H/B?3SFSU>RBO(QG. Z@X_
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H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>bpth-20250110.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/10/2025 7:43:59 PM-->
<!--Modified on: 1/10/2025 7:43:59 PM-->
<xsd:schema targetNamespace="http://www.biopathholdings.com/20250110" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:bpth="http://www.biopathholdings.com/20250110" xmlns:rxp="http://xbrl.sec.gov/rxp/2024" xmlns:snj="http://xbrl.sec.gov/snj/2024" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="bpth-20250110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="bpth-20250110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>bpth-20250110_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/10/2025 7:43:59 PM-->
<!--Modified on: 1/10/2025 7:43:59 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>bpth-20250110_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 1/10/2025 7:43:59 PM-->
<!--Modified on: 1/10/2025 7:43:59 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="bpth-20250110.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638721350396523719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638721350396523719" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638721350396563736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638721350396563736" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638721350396563736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638721350396563736" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638721350396563736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638721350396563736" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638721350396563736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638721350396563736" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638721350396563736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638721350396563736" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638721350396563736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638721350396563736" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638721350396563736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638721350396563736" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638721350396563736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638721350396563736" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638721350396563736" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638721350396563736" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638721350396573737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638721350396573737" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638721350396573737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638721350396573737" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638721350396573737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638721350396573737" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638721350396573737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638721350396573737" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638721350396573737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638721350396573737" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638721350396573737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638721350396573737" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638721350396573737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638721350396573737" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638721350396573737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638721350396573737" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638721350396573737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638721350396573737" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638721350396573737" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638721350396573737" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638721350396583744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638721350396583744" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638721350396583744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638721350396583744" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638721350396583744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638721350396583744" order="23" use="optional" priority="2" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46284972907888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIO-PATH HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0652870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4710 Bellaire Boulevard<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bellaire<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">742-1357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BPTH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001133818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " #K@2I:EXJ[',     3 @
M"P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%
MBD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L
M'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+
M,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO
M8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( .N!*EH<.&7J
M/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y $U"+5$2X
ME#Z0JA:5BON2=8C%/B*O RU?7R=15*1>>O)Z;(UG9A?G2,=]C$?UY5U(A:Z9
MFWF6I;(&;])-;"#(I(KD#4M+ARPU!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU$QE*
MQA@$[( =PCG]SKM6G3#A'AWR=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\Q,#&;4N*
MSA5Z,@QV0(SE'WC;B?PT^]0C;/8?1H04>I8+8864N-_H^8UH/($L#UW+\0D=
M ZT,PS/%ML%PZ&C$179EH\]AK$.(<_I/C+&JL(15+%L/@8<<"5PG,*0:FZ15
M,!X*/:XH$ZQZ#"PAJ748J&2W<RJGUW9PS2+W*D.:HPQH;0?AHUH+%0:P;W(@
M"2[)E1M27>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " #K@2I:
M)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]
M#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H
M%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>
M[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9
MBBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @
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MX3]>?P%02P$"% ,4    " #K@2I:!T%-8H$   "Q    $
M@ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .N!*EJ(&#SL[@
M "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4
M Q0    ( .N!*EJ97)PC$ 8  )PG   3              "  <P!  !X;"]T
M:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ZX$J6HRZT&%L!   5A$  !@
M             ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4
M Q0    ( .N!*EJ?H!OPL0(  .(,   -              "  :\,  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ ZX$J6I>*NQS     $P(   L
M     ( !BP\  %]R96QS+RYR96QS4$L! A0#%     @ ZX$J6APX9>H_ 0
M/ (   \              ( !=!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( .N!*EHD'INBK0   /@!   :              "  > 1  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( .N!*EIED'F2&0$  ,\#
M   3              "  <42  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   )  D /@(   \4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="bpth-20250110x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bpth-20250110.xsd</File>
    <File>bpth-20250110_lab.xml</File>
    <File>bpth-20250110_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="bpth-20250110x8k.htm">bpth-20250110x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bpth-20250110x8k.htm": {
   "nsprefix": "bpth",
   "nsuri": "http://www.biopathholdings.com/20250110",
   "dts": {
    "schema": {
     "local": [
      "bpth-20250110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "bpth-20250110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bpth-20250110_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "bpth-20250110x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bpth-20250110x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bpth-20250110x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.biopathholdings.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-25-000123-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-000123-xbrl.zip
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M=!G#7Y<G"O .-O+Y+F93A(;CZC=02P,$%     @ ZX$J6HN+82B!!0  A3X
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MVY=_)F)($(V2M+].\45GSOFB[[JKU:J[.NE2-A/G]SSWZ^WP/IRC)' P27E
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MK()*= .YSZ#Y2L1@: 5D@1,0ST-)AAS*R"*K\#+4)%76U1RGZ5PVPXDYNI#
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M:&-M>5;X(3Y5;&U"_AC^P#S\'U!+ P04    " #K@2I:"<'/*H\6  #^;
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M(.(>M84/E\4Q"N*3_X Q?X_CUWL\?I[I6-=8+L/<I_D%C"0.7KQN3*TKHT@
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MF)=XEMD&[)!9I@QO7]C&B8H@BI:M2).E&? I 1.]A/:_ ]E.O!R)-QH4JG(
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M,=< ;I__'?H3I$9@2>8&1F3;Y,3HM,TW1?#$+Q^1 M\7 UV'@+DE_!-@T1<
M/)\,9=[UQ"0)0^L5GY,@[!EFH/2U&GK(BSJ&E Y7"&YW84_KUEWC$>VT]B3&
MT&82/Z<]M5U0&.@4J=D2,36[?RW"L(2GX3#<2@*.O*HDY5<H5Q.R*I2J 9C0
M8K#,%..'0%67>6MI"3;FVD'9R2],BTD7Z6,(Z@%;()W+9J!VID.NA\GKGLF
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M'Z=$"M5!UF&)Q+L(H,$0#5+^(6]SVJVI"@8NGD!"L&B_^/%H?_ %;$^C0J;
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M,#(U,#$Q,%]P<F4N>&UL4$L! A0#%     @ ZX$J6C1H3F,]%   ()P  !0
M             ( !10X  &)P=&@M,C R-3 Q,3!X.&LN:'1M4$L! A0#%
M  @ ZX$J6@G!SRJ/%@  _FP  !@              ( !M"(  &)P=&@M,C R
F-3 Q,3!X97@Y.60Q+FAT;5!+!08     !0 % $T!  !Y.0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>bpth-20250110x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bpth-20250110.xsd" xlink:type="simple"/>
    <context id="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001133818</identifier>
        </entity>
        <period>
            <startDate>2025-01-10</startDate>
            <endDate>2025-01-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_yjcFpQsgIEOKWpV7R2277A_2_1">0001133818</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_jZhUsFsLLkuqzil6UW9vfw_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_NGTMmHhZPkO7Gi-KAYdkCg">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_sPUBaSvaqUWrWosRHHTocg">2025-01-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_hueI6ui5MkuypjsGQX1-bQ">BIO-PATH HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_9T_M8owlL0Se5AIhwVuygg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_TaRGEEgpb06lJnlZ75mDGw_1_2">001-36333</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_T6WWZ-JONE6YvjCGGfuWlA_1_4">87-0652870</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_Mj7AJt2nVE20bu4-keeE_A">4710 Bellaire Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_wEsVccafY0qCzI5__9GxCw">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_5-dZTqpOSUqcJa1IDb1Www">Bellaire</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_Ibut8vBwik2TyyvL6sPC_w">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_8NXNcfObNU--p3hUYO6WNQ_1_2">77401</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_dLkV_PBbnESFexeIv0BD-g">832</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_BHs3bGy_Jki8JdNbpkXs_A">742-1357</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_nk09Mq3aNU-DYisFGLsaeA_1_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_sSvqhKuAz0qkIoz-3-hsAw_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_Y3BkdsRC_0SgximsULO2PQ_3_0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_B041nSXjJUucWJnXknuGbg_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_4rQ8W00AEkSdLf-Af2PkSg_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Tc_eO1IJwELkUSQmtoc6-GcXQ_2_2">BPTH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_beFinRF-q0ChyoM3PUSgdg">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_10_2025_To_1_10_2025_bTp7LpPROUqOROp_sGOEZg"
      id="Narr_Ut5KOlhftEyG84YDIkESqg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
